Table 5 Significant variables in the bivariate analysis of patients receiving vs. not receiving antifungals, [n (%)] except where indicated
|  | Total patients (n = 245) | Colonised (n = 106) | Aspergillosis (n = 139) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Treated (n = 104) | Non-treated (n = 141) | p | Treated (n = 31) | Non-treated (n = 75) | p | Treated (n = 110) | Non-treated (n = 29) | p |
Age (X ± SD) | 66.7 ± 15.9 | 71.4 ± 13.8 | 0.016 | 66.0 ± 16.7 | 70.4 ± 15.7 | 0.086 | 66.9 ± 15.8 | 73.9 ± 6.6 | 0.001 |
Days to isolation (X ± SD) | 12.3 ± 12.2 | 7.6 ± 7.6 | 0.001 | 8.9 ± 6.6 | 7.0 ± 6.5 | 0.096 | 13.2 ± 13.1 | 9.1 ± 9.6 | 0.046 |
COPD | 90 (63.8) | 83 (79.8) | 0.007 | 15 (48.4) | 58 (77.3) | 0.005 | 75 (68.2) | 25 (86.2) | 0.064 |
GOLD III + IV | 57 (40.4) | 54 (51.9) | 0.074 | 8 (53.4) | 32 (58.2) | 0.568 | 49 (65.3) | 22 (88.0) | 0.041 |
COPD exacerbation | 22 (15.6) | 3 (2.9) | 0.625 | 6 (19.4) | 29 (38.7) | 0.070 | 56 (50.9) | 20 (69.0) | 0.082 |
Severe liver disease | 3 (2.1) | 8 (7.7) | 0.058 | 1 (3.2) | 6 (8.0) | 0.671 | 2 (1.8) | 2 (6.9) | 0.192 |
Stroke | 4 (2.8) | 6 (5.8) | 0.332 | 1 (3.2) | 2 (2.7) | 1.000 | 3 (2.7) | 4 (13.8) | 0.035 |
APACHE II (X ± SD) | 13.8 ± 7.6 | 12.3 ± 5.6 | 0.076 | 12.6 ± 7.5 | 11.2 ± 5.4 | 0.291 | 14.1 ± 7.6 | 15.1 ± 5.1 | 0.439 |
ICU admission | 47 (33.3) | 11 (10.6) | 0.001 | 10 (32.3) | 5 (6.7) | 0.001 | 37 (33.6) | 6 (20.7) | 0.259 |
ICU stay (days; X ± SD) | 7.6 ± 7.9 | 10.0 ± 3.4 | 0.113 | 2.1 ± 4.8 | 0.3 ± 1.8 | 0.014 | 7.9 ± 8.3 | 2.0 ± 2.8 | 0.046 |
Pleuritic pain | 19 (13.5) | 6 (5.8) | 0.049 | 2 (6.5) | 5 (6.7) | 1.00 | 17 (15.5) | 1 (3.4) | 0.121 |
Bronchospasm | 66 (46.8) | 23 (22.1) | 0.001 | 8 (25.8) | 17 (22.7) | 0.803 | 58 (52.7) | 6 (20.7) | 0.003 |
Infiltrates (X-ray / CT) | 102 (72.3) | 47 (45.2) | 0.001 | 18 (58.1) | 31 (41.3) | 0.137 | 84 (76.4) | 16 (55.2) | 0.024 |
Cavitations (X-ray / CT) | 31 (22.0) | 7 (6.7) | 0.001 | 1 (3.2) | 4 (5.3) | 0.642 | 30 (27.3) | 3 (10.3) | 0.084 |
Nodules (X-ray / CT) | 48 (34.0) | 22 (21.2) | 0.027 | 5 (16.1) | 16 (21.3) | 0.541 | 43 (39.1) | 6 (20.7) | 0.081 |
Treatment with Quinolones | 41 (29.1) | 42 (40.4) | 0.065 | 12 (38.7) | 27 (36.0) | 0.827 | 29 (26.4) | 15 (51.7) | 0.009 |